

ARRDC1 and ARRDC3 facilitate YAP1 degradation

Supplementary Table 1. Sequences for shRNAs, siRNAs and primers used for qRT-PCR

Sequences for siRNAs		
Gene	Sequence	
sh-ARRDC1#1	5'-CTCGTGTCTATATCTTGA-3'	
sh-ARRDC1#2	5'-CCAAGAAGTTCTCCTACAA-3'	
sh-ARRDC3#1	5'-GGCCTTGGCTACTACCAGT-3'	
sh-ARRDC3#2	5'-GCGTGGAAATTTACTAAT-3'	
sh-YAP1	5'-CUGCCACCAAG UAGAUAAAT-3'	
sh-control	5'-TTCTCCGAACGTGTCACGT-3'	
Sequences for primers		
Gene	RT Forward	RT Reverse
ARRDC1	5'-CAGTGCCCACTACCAGCAC-3'	5'-ATAGGGGTAGCCCAAGAAC-3'
ARRDC3	5'-CATCTTAATTGGGCACGAAA-3'	5'-GTGGAAGCTCGAAGCTGAAT-3'
CYR61	5'-CTGCCTTAGTCGTCACCC-3'	5'-CGCCGAAGTTGCATTCCAG-3'
CTGF	5'-ACTATGATTAGACCAACTG-3'	5'-TGTCTCTTCCAGGTCAG-3'

Supplementary Table 2. Antibody list

Antibody epitope	Mono/polyclonal	Host	Source	Catalog No.	Application
ARRDC1	Monoclonal	Mouse	Santa Cruz	sc-398652	WB, IP
ARRDC3	Polyclonal	Rabbit	Santa Cruz	sc-135442	WB, IP, IHC
YAP1	Monoclonal	Rabbit	Cell Signaling	#14074	WB, IP, IHC
Actin	Monoclonal	Mouse	Sigma	A2228	WB
E-Cadherin	Polyclonal	Rabbit	Proteintech	20874	WB
N-Cadherin	Polyclonal	Rabbit	Proteintech	22018	WB
Vimentin	Polyclonal	Rabbit	Proteintech	10366	WB
Myc	Polyclonal	Rabbit	MBL	562	WB, IF
HA	Monoclonal	Mouse	MBL	M180-3	WB
FLAG	Monoclonal	Mouse	Sigma	F1804	WB, IF, IP

IF: immunofluorescence; IP: immunoprecipitation; IHC: immunohistochemistry; WB: Western blotting.

Supplementary Table 3. Patient characteristics and clinicopathological factors by ARRDC3 and YAP1 expression

	ARRDC3 neg	ARRDC3 pos	<i>p</i> value	YAP1 neg	YAP1 pos	<i>P</i> value
NO. of patients	14	26		4	36	
Median age (years)	57.3	52.9		53	56.1	
Sex			0.7410			0.6235
Male	8	12		3	20	
Female	6	14		1	16	
Fuhrman grade			0.0020			0.0008
Low (G1/G2)	4	21		4	4	
High (G3/G4)	10	5		0	32	
Primary T stage			0.0009			0.0090
Low (pT1/pT2)	3	25		3	6	
High (pT3/pT4)	11	3		1	30	